• Genfit released an investor presentation outlining the long-term commercial opportunity for its MASH blood-based diagnostics technology.
• Highlights U.S. commercialization via Labcorp as a laboratory-developed test, with initial Medicare reimbursement for eligible patients.
• Frames market inflection around resmetirom approval, shifting bottlenecks toward patient identification, stratification, monitoring.
• Reiterates focus on non-invasive testing to identify “at-risk MASH,” defined as biopsy-confirmed MASH with MAS≥4, fibrosis stage ≥2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.